Yizhuang Biopharma Files IPO Prospectus as Recognized 'Outstanding Enterprise' at CSGCT 2025

Beijing Yizhuang International BiotechPharmaceutical Investment Management Co., Ltd.

Booth No.: B18

Beijing E-Town International Biopharmaceutical Investment Management Co., Ltd. (hereinafter referred to as“Yizhuang Biopharmaceuticals") is dedicated toBuilding a Biotechnology and General Health Industry Platform with Nationwide Leadership. Relying on“Industrial Bureau + Platform Company” Efficient Government-Enterprise Collaboration Advantages, Based onIndustrial Development, Industrial Investment Promotion, Industrial Investment, and Industrial ServicesAs a key business segment, the company covers the entire industry chain—from early-stage planning and research, development and construction, to asset operation, investment promotion services, and industrial facilitation. By aggregating industrial resources and fostering value co-creation, it deepens the cluster effect of the Beijing Economic-Technological Development Area’s hundred-billion-yuan industrial clusters, comprehensively builds a new highland for the capital’s biomedical and health industry, and supports Beijing’s development into an international science and technology innovation center.

In terms of industrial services,BuiltEtown Bio Public Technology Service Platform，Responsible for15,000 m² Laboratory SpaceofOperations and Management. We provide specialized technical services to pharmaceutical companies, biotechnology firms, research institutes, and hospitals, with a service scope covering the entire process from drug discovery to clinical trial application. The platform is equipped with professional R&D laboratories, a small animal experimentation center, pilot-scale production workshops, and cellCDMOPublic Techsurgical service platform, exceeding2,000 units of laboratory instruments and equipment have formedA Tripartite Service Matrix Comprising Specialized Spatial Clusters, Technology-Service Empowerment, and Instrument-and-Equipment SharingIt has established a new model of an innovative service platform that enables the co-construction, sharing, and coordinated development of biomedical resources, as well as the aggregation of professional service resources. This model has effectively reduced operational costs for small and medium-sized enterprises (SMEs) in the biopharmaceutical sector and played a positive role in promoting the rapid development of the industry.

Total investment of nearlyWith an investment of RMB 200 million, the four-story facility houses 16 GMP-compliant production lines, including six for clinical-grade cells, eight for commercial-scale cells, and two for gene therapy. The commercial production lines operate in Grade B cleanroom environments, while the clinical production lines operate in Grade C environments. Equipped with over 500 specialized devices such as bioreactors and sterile filling lines, the facility provides comprehensive spatial support for the research, development, and manufacturing of cell and gene therapy products. An additional floor features two production lines dedicated to positive-cell therapies, offering “customized hope” for patients with no other treatment options and filling gaps in clinical care.

Over 2,000 square meters of GMP-compliant facility, equipped with three pilot-scale production lines centered on large-scale mammalian cell culture. Capable of providing pilot production services for various macromolecular biologics expressed in mammalian cells, including viral vector products, vaccine products, antibodies, and other recombinant therapeutics. All production lines are supported by shared utility systems such as purified water, water for injection, and compressed air. The viral vector production line has completed registration for Biosafety Level 2 (BSL-2) compliance.

Clean Cell Room, P2 Laboratory

We offer laboratory cleanroom rentals specifically designed for high-precision requirements in scientific research and biopharmaceuticals, strictly ensuring sterility, dust-free conditions, and stable temperature and humidity. Areas range fromRanging from 10 to 150 square meters, the facility includes more than ten Grade B and Grade C cleanrooms, catering to the needs of experimental projects of varying scales.P2 LaboratoryCapable of conducting Biosafety Level 2 (BSL-2) cell and microbiology experiments. The cleanroom is equipped with CO₂ incubators, biological safety cabinets, centrifuges,Inverted Microscope, refrigerators, water baths, and other equipment.

Animal Foster Care

Providing professional services for the housing and management of laboratory animals, such as rats and mice, to scientific research institutions, pharmaceutical R&D enterprises, university laboratories, and others, coveringSPF (Specific Pathogen-Free) and BSL-2 (Biosafety Level 2) housing, meeting ABSL-2 requirements for infectious disease studies (including 24-hour environmental monitoring, routine animal care, and sentinel mouse surveillance). We provide technical services to support enterprises in efficiently conducting animal experiments for drug efficacy evaluation, vaccine assessment, and the establishment of animal disease models.

Technical Service Empowerment

• Testing and Inspection Platform: Covers comprehensive testing of pharmaceuticals, pharmaceutical water, and clean environments, withCNAS Testing Accreditation;

•Process Development Platform: Process development services including prokaryotic fermentation, cell culture, and protein purification;

•Contract Manufacturing Services: Provision of preclinical samples, clinical samples, andIITContract manufacturing services for experimental samples.

To drive technological breakthroughs, industrial integration, policy alignment, and international cooperation in China’s cell and gene therapy (CGT) sector, and to propel the Chinese CGT industry to the forefront of global competition, the China Society for Cell and Gene Therapy (CSGCT) Conference was established.

Leveraging its close ties with the American Society of Gene & Cell Therapy (ASGCT), the 2025 CSGCT Annual Meeting will bring togetherleading scientists, clinical experts, multinational pharmaceutical companies, and overseas investment institutions, bringing the mostCutting-edge research advancements, technologies and applications, market access information, high-quality collaborative projects, and matchmaking with overseas investors and investment opportunities, building a platform for in-depth exchange and cooperation between China’s cell and gene therapy industry and the global industrial chain.

This conference closely aligns with the industry’s hotspots, pain points, and bottlenecks, featuring1 Main Forum + 18 High-End Sub-Forums, coveringLatest Advances in Global Gene Therapy, Immune Cell Therapy, In Vivo CAR-T, Adult Stem Cells and Exosomes, iPSC-Derived Cell Therapies, Small Nucleic Acid Drugs, Gene Editing, Oncolytic Viruses, and Tumor Vaccines, as well as CMC and Testing, AI-Driven Drug R&D, Registration and Regulation, Investment and Financing, and BD MatchmakingWaitIn-depth coverage of the entire industry chain.

2025 2nd China Society for Gene and Cell Therapy (CSGCT) Congress

September 12-13, 2025

Zhongguancun National Independent Innovation Demonstration Zone Exhibition and Trading Center [Conference Center]

For more details, scan the QR code to visit the official conference website.